Novartis AG (NOVN.SW)

90.54 +0.76 (+0.85%) 收市：05:31PM CEST

Novartis AG

Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com

版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 76,057

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Vasant Narasimhan M.D.	Chief Executive Officer	7.33M	無	1976
Mr. Harry Kirsch	Chief Financial Officer	3.65M	無	1965
Mr. Victor Bulto	President of US	3M	無	1978
Dr. Patrick Horber M.D.	President of International	6.68M	無	1970
Dr. Steffen Lang Ph.D.	President of Operations	2.14M	無	1967
Paul Penepent	Head of Group Financial Reporting and Accounting	無	無	無
Ms. Sloan Simpson	Global Head of Investor Relations	無	無	無
Dr. Klaus Moosmayer Ph.D.	Chief Ethics, Risk & Compliance Officer	1.42M	無	1968
Ms. Karen L. Hale	Chief Legal Officer	2.14M	無	1968
Dr. Robert Kowalski Pharm.D.	Chief People & Organization Officer	1.92M	無	1968

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 CHF。

描述

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

公司管治

截至 2024年5月1日 止，Novartis AG 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中：1；董事會：2；股東權利：1；現金賠償：3。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。